anthera pharmaceuticals inc (ANTH) Key Developments
Anthera Pharmaceuticals, Inc. Announces Initiation of the SOLUTION Clinical Study of Oral Sollpura (Liprotamase) Unit-Matched Therapy of Non-Porcine Origin in People with Cystic Fibrosis
Oct 2 15
Anthera Pharmaceuticals, Inc. announced the initiation of the SOLUTION (Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in People With Cystic Fibrosis) Phase 3 clinical study evaluating the efficacy and safety of Sollpura® (liprotamase), a microbial derived, biotech pancreatic enzyme replacement therapy (PERT), compared to an approved, porcine-derived, enteric-coated product for the treatment of exocrine pancreatic insufficiency (EPI). The Phase 3 SOLUTION clinical study is a multicenter, randomized, open-label, assessor-blind, non-inferiority, active-comparator study designed to evaluate the efficacy and safety of Sollpura in people with EPI due to cystic fibrosis. This pivotal study is intended to evaluate the non-inferiority of Sollpura compared with a commercially available PERT in a population enriched for PERT responders. The primary efficacy endpoint of this study will be comparative efficacy measured as the change in the coefficient of fat absorption (CFA) at the end of therapy. Results from the SOLUTION clinical study are anticipated to support marketing approval for Sollpura as a treatment for exocrine pancreatic insufficiency.
Anthera Announces Termination of Blisibimod Partnership in Japan by Zenyaku
Sep 14 15
Anthera Pharmaceuticals, Inc. announced receipt of a termination notice from its development partner in Japan, Zenyaku, terminating the December 2014 Collaboration and License Agreement (the License Agreement") effective January 7, 2016. The termination was at will" and alleged no breach of the License Agreement by Anthera. At the time of the notification, no patients had been enrolled in any blisibimod clinical studies in the Zenyaku territory and Zenyaku had not purchased any blisibimod product from Anthera.
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 10 15
Anthera Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's total revenues were $289,000. Loss from operations was $8,846,000 compared to $6,865,000 a year ago. Net loss was $8,895,000 compared to $7,256,000 a year ago. Net loss per share attributable to common stockholders - basic and diluted was $0.25 compared to $0.34 a year ago.
For the six months, the company's total revenues were $534,000. Loss from operations was $16,503,000 compared to $14,474,000 a year ago. Net loss was $16,555,000 compared to $15,172,000 a year ago. Net loss per share attributable to common stockholders - basic and diluted was $0.52 compared to $0.73 a year ago. The increase in net loss both quarterly and year-to-date is mainly driven by higher clinical development expense for blisibimod program and manufacturing and study preparation expenses for the Sollpura development program.
Anthera Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 10, 2015
Jul 30 15
Anthera Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 10, 2015
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) added to Russell 2000 Index
Jun 30 15
Anthera Pharmaceuticals, Inc. will be added to Russell 2000 Index